A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy

Blood

Volumn 124, Issue 8, 2014, Pages 1277-1287

  Philip, Brian ^a   Kokalaki, Evangelia ^a   Mekkaoui, Leila ^a   Thomas, Simon ^a   Straathof, Karin ^a   Flutter, Barry ^a   Marin, Virna ^b   Marafioti, Teresa ^a   Chakraverty, Ronjon ^a   Linch, David ^a   Quezada, Sergio A ^a   Peggs, Karl S ^a   Pule, Martin ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD34 ANTIGEN; CD8 ANTIGEN; OFATUMUMAB; PROTEIN; RITUXIMAB; RQR8 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL THERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOTOXICITY; FLOW CYTOMETRY; GENETIC ENGINEERING; IN VITRO STUDY; IN VIVO STUDY; MARKER GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SUICIDE GENE; SUICIDE GENE THERAPY; T LYMPHOCYTE;

ALLOGRAFTS; ANIMALS; ANTIGENS, CD20; ANTIGENS, CD34; EPITOPES; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; MICE; MICE, INBRED BALB C; NEOPLASMS; T-LYMPHOCYTES;

EID: 84907373133     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-545020     Document Type: Article

References (39)

1. Gilham DE, Debets R, Pule M, Hawkins RE, Abken H. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med. 2012;18(7):377-384.
2. Bridgeman JS, Gilham DE, Hawkins RE, Cheadle EJ. The second cellular therapy of cancer symposium, 27-29 March 2009, Milan, Italy. Cancer Immunol Immunother. 2010;59(6):971-974.
3. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-851.
4. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 2010;18(4):666-668.
5. Brentjens RJ, Rivière I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817-4828.
6. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535-546.
7. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24(13):e20-e22.
8. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733.
9. Grupp SA, Porter DL, Teachey DT, et al. CD19-redirected chimeric antigen receptor T (CART19) cells induce a cytokine release syndrome (CRS) and induction of treatable macrophage activation syndrome (MAS) that can be managed by the IL-6 antagonist tocilizumab (toc) [abstract]. Blood. 2012;120(21):2604.
10. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 2009;10(5):489-500.
11. Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673-1683.
12. Mavilio F, Ferrari G, Rossini S, et al. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood. 1994;83(7):1988-1997. (Pubitemid 24107926)
13. Fehse B, Richters A, Putimtseva-Scharf K, et al. CD34 splice variant: an attractive marker for selection of gene-modified cells. Mol. Ther. 2000;1(5 Pt 1):448-456.
14. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci U S A. 1995;92(15):6733-6737.
15. Ai HW, Shaner NC, Cheng Z, Tsien RY, Campbell RE. Exploration of new chromophore structures leads to the identification of improved blue fluorescent proteins. Biochemistry. 2007;46(20):5904-5910. (Pubitemid 46799153)
16. Bochkov YA, Palmenberg AC. Translational efficiency of EMCV IRES in bicistronic vectors is dependent upon IRES sequence and gene location. Biotechniques. 2006;41(3):283-284, 286, 288.
17. Donnelly ML, Hughes LE, Luke G, et al. The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J Gen Virol. 2001;82(Pt 5):1027-1041. (Pubitemid 32454603)
18. Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol. 1995;69(12):7430-7436.
19. Persons DA, Mehaffey MG, Kaleko M, Nienhuis AW, Vanin EF. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene. Blood Cells Mol Dis. 1998;24(2):167-182. (Pubitemid 28365736)
20. Schleiss MR, Degnin CR, Geballe AP. Translational control of human cytomegalovirus gp48 expression. J Virol. 1991;65(12):6782-6789.
21. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106(1):376-383. (Pubitemid 40967217)
22. Straathof KC, Pulè MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105(11):4247-4254. (Pubitemid 40720769)
23. Leahy DJ. A structural view of CD4 and CD8. FASEB J. 1995;9(1):17-25.
24. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood. 2006;108(6):1975-1978. (Pubitemid 44395009)
25. Du J, Wang H, Zhong C, et al. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem. 2007;282(20):15073-15080. (Pubitemid 47093338)
26. Perosa F, Favoino E, Vicenti C, Merchionne F, Dammacco F. Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy. J Immunol. 2007;179(11):7967-7974.
27. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin. Oncol. 1997;15(10):3266-3274. (Pubitemid 27419340)
28. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362-371. (Pubitemid 43939148)
29. Hussain R, Dawood G, Abrar N, et al. Selective increases in antibody isotypes and immunoglobulin G subclass responses to secreted antigens in tuberculosis patients and healthy household contacts of the patients. Clin Diagn Lab Immunol. 1995;2(6):726-732.
30. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med. 1996;2(2):216-223. (Pubitemid 26057556)
31. Bonini C, Bondanza A, Perna SK, et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther. 2007;15(7):1248-1252. (Pubitemid 46965319)
32. Lange C, Li Z, Fang L, Baum C, Fehse B. CD34 modulates the trafficking behavior of hematopoietic cells in vivo. Stem Cells Dev. 2007;16(2):297-304. (Pubitemid 46799506)
33. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359-7368.
34. Wang X, Chang WC, Wong CW, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118(5):1255-1263.
35. Kieback E, Charo J, Sommermeyer D, Blankenstein T, Uckert W. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc Natl Acad Sci USA. 2008;105(2):623-628. (Pubitemid 351171758)
36. Introna M, Barbui AM, Bambacioni F, et al. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther. 2000; 11(4):611-620. (Pubitemid 30134304)
37. Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. Health Technol Assess. 2012;16(37):1-253, iii-iv.
38. Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009;9(1):10-25.
39. Wehler TC, Graf C, Möhler M, et al. Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective. J Cancer Res Clin Oncol. 2013;139(10):1667-1672.